Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

NCT03050411 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT03050411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03050411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Lead sponsor
Peking University Third Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2016
Completion date
October 31, 2019
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonsmall cell lung cancer